The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Toho to Thoroughly Implement Drug Distribution GL, Focus on Cost-Cutting in Response to Impact of Drug Pricing Reform: Pres.
March 20, 2018
-
REGULATORY MHLW Health Policy Chief Questions Volume-Focused Sales Strategies, Urges Drug Makers to Shift to Healthy Lifespan Extension
March 19, 2018
-
BUSINESS Shionogi Nabs Rights to Osaka Upstart’s Tissue Regeneration-Inducing Peptide
March 16, 2018
-
BUSINESS Japan Likely the Only Negative Growth Pharma Market in 2018-2022: IQVIA
March 16, 2018
-
BUSINESS Shionogi’s Single-Dose Flu Med Xofluza Hits Japan Shelves
March 15, 2018
-
BUSINESS Gilead Japan Rolling Up Its Sleeves for Foray into Oncology/Inflammation Market
March 14, 2018
-
TRENDS Merck Deal Could Pave Way for Eisai to Hit 800 Billion Yen Sales Target in FY2020
March 13, 2018
-
BUSINESS Eisai Bags Up-to-US$5.76 Billion Lenvima Alliance with Merck
March 9, 2018
-
BUSINESS Foreign Drug Makers Increased Market Share to Over 60% among Top 20 Makers in 2017
March 9, 2018
-
BUSINESS Torii’s Futhan to Get 43.4% Price Cut in April, Urinorm 24.6%: Top 5 Product Survey
March 8, 2018
-
BUSINESS Mid-Sized Japan Makers to Take Heaviest Hit from April Price Cut, Bigger Peers See Smaller Reductions: Jiho Survey
March 7, 2018
-
REGULATORY Winners and Losers of New PMP Criteria: Januvia Earns 1st Premium while Xarelto, Humira Miss It
March 6, 2018
-
REGULATORY 314 APIs Eligible for Price Maintenance Premium in FY2018, Down from 416
March 5, 2018
-
REGULATORY Opdivo Faces 23.8% Price Cut as Slew of Reduction Rules Apply; Nexium Down 16.1% on Huge Seller Slash
March 5, 2018
-
BUSINESS Japan Ethical Drug Sales Slip 1.0% in 2017, Harvoni Drops Out of Top 10 List: IQVIA
March 2, 2018
-
BUSINESS Despite Solid Mainstays, Pfizer Japan’s FY2017 Sales Down 6.6% on LLPs
March 2, 2018
-
ACADEMIA Nephrology Society Compiles New Drug Development Guidelines for Advanced CKD; Will Guidelines for Early-Stage CKD Follow?
March 1, 2018
-
BUSINESS Kissei Makes Full Foray into IBD Arena with Rectabul, Set to Enrich “Unmet Needs” Portfolio
February 27, 2018
-
BUSINESS Nomura Picked as Next Chief of Sumitomo Dainippon, Vows to Build Peripheral Healthcare Biz
February 26, 2018
-
REGULATORY Shionogi’s Single-Dose Flu Med Gets Accelerated OK
February 26, 2018
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…